+359.1%
VST vs MRNA
+30.4%
+328.7%
-48.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.6% | -3.6% | +5.2% | +1.7% |
| 7D | +9.9% | -9.0% | +18.9% | +10.2% |
| 30D | +7.9% | +137.2% | -129.2% | +2.3% |
| 3M | +3.4% | +194.8% | -191.4% | -4.4% |
| 6M | -4.1% | +167.2% | -171.3% | -10.9% |
| YTD | -5.7% | +375.9% | -381.6% | -17.5% |
| 1Y | -18.9% | +465.2% | -484.0% | -30.8% |
| 3Y | +359.1% | +30.4% | +328.7% | +308.0% |
| All | +359.1% | +30.4% | +328.7% | +308.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling